Mindstate Design Labs has announced major news, receiving both FDA and European Medicines Agency (EMA) approval to commence human trials of its compound, MSD-001. This approval is a clinical validation for Mindstate’s advanced neurotech AI platform, Osmanthus, which specializes in the precision design of altered states of consciousness.